Progyny Stock Is Falling After Earnings. What the IVF Ruling Means for It.
- Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.
- 02/28/2024
|
Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
- Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
- 02/27/2024
|
Alabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers
- This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state's largest healthcare provider, to cease all in vitro fertilization (IVF) treatments.
- 02/23/2024
|
3 Cash-Rich Stocks to Buy for Peace of MInd in 2024
- One of the fun things about writing about stocks for a living is the library of content you can draw upon for inspiration. Back in June 2020, we were deep in the pandemic, so I wrote a piece about cash-rich stocks to buy for peace of mind.
- 01/24/2024
|
3 Mid-Cap Stocks Poised for a Breakout in 2024
- Important voices in the investment world predict that 2024 could be a very strong year for mid-cap stocks. Janus Henderson portfolio manager Brian Demain believes the outlook for mid caps looks favorable as rate hikes slow and cuts draw nearer.
- 01/16/2024
|
Progyny Inc.: Resilient Business Model With Strong Growth Ahead
- Progyny, Inc. demonstrates strong resilience and sustained growth potential in a weak macro backdrop. The company's revenue grew 37% year-over-year, beating estimates, with strong performance in fertility benefit services and pharmacy revenue. The contract with the federal government presents a major growth opportunity and the potential for upselling.
- 12/16/2023
|
Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why
- Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 11/13/2023
|
Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023, at 10:30 A.M. Eastern Time.
- 11/10/2023
|
New Strong Buy Stocks for October 30th
- CVEO, FBP, EIG, MNTX and PGNY have been added to the Zacks Rank #1 (Strong Buy) List on October 30, 2023.
- 10/30/2023
|
New Strong Buy Stocks for October 17th
- MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
- 10/17/2023
|
Progyny: 4 Reasons I Bought This Stock
- There are several clear reasons to consider Progyny stock. The company's worth is overlooked, making it a sneaky value play for investors. Here's how Progyny's unique position in the industry and financial health make it an attractive acquisition target.
- 10/15/2023
|
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
- Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
- 09/29/2023
|
3 Reasons Growth Investors Will Love Progyny (PGNY)
- Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 09/01/2023
|
Wall Street Loves These 3 Growth Stocks; Should You?
- Nvidia and artificial intelligence dominate recent headlines -- deservedly so. But there are many diverse companies getting bullish nods from Wall Street.
- 08/29/2023
|
Here is Why Growth Investors Should Buy Progyny (PGNY) Now
- Progyny (PGNY) could produce exceptional returns because of its solid growth attributes.
- 08/16/2023
|
Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Progyny (PGNY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/03/2023
|
MD vs. PGNY: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical Services sector have probably already heard of Pediatrix Medical Group (MD) and Progyny (PGNY). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/18/2023
|
7 Growth Stocks to Buy to go Beyond the ‘Magnificent 7'
- The ‘Magnificent 7' stocks have garnered a lot of attention in 2023 for pulling equities out of a bear market and into a bull run. Headlines have seized upon their colossal influence noting that they are largely responsible for the turnaround.
- 07/17/2023
|
Small Growth Stocks Are Finally Catching Big Tech
- The guppies are finally swimming with the whales. The guppies, of course, are the highest growth stocks, and the whales are the Big Tech names.
- 07/11/2023
|
4 Top Stocks to Buy in July and Hold Forever
- Doximity's massive platform for doctors is the perfect setting for healthcare advertisers. Declining fertility trends make Progyny's services all the more important to its customers.
- 07/10/2023
|
Progyny: No Issues With Growing Healthily Ahead
- Progyny: No Issues With Growing Healthily Ahead
- 06/29/2023
|
These 3 Unique Stocks Have Undeniable Long-Term Upside
- A tectonic demographic shift is boosting fertility specialist Progyny. Streaming is driving massive growth for innovative demand-side ad platform The Trade Desk.
- 06/15/2023
|
Should You Buy Progyny (PGNY) After Golden Cross?
- From a technical perspective, Progyny, Inc. (PGNY) is looking like an interesting pick, as it just reached a key level of support. PGNY's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
- 06/12/2023
|
Progyny, Inc. to Present at Jefferies 2023 Healthcare Conference
- NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies 2023 Healthcare Conference on Wednesday, June 7, 2023, at 2:00 P.M. Eastern Time.
- 06/05/2023
|
Have $1,000? These 3 Stocks Could Be Bargain Buys for 2023 and Beyond.
- A thousand bucks doesn't buy what it used to, given recent inflation; But investing it is the best way to make it grow. These individual stocks are top contenders for investing dollars.
- 05/24/2023
|
Looking for a Growth Stock? 3 Reasons Why Progyny (PGNY) is a Solid Choice
- Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.
- 05/17/2023
|
Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy?
- Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 05/17/2023
|
Why Progyny Caught My Eye; Is It A Buy?
- Sparsely followed Progyny, Inc. is quietly making industry waves. The target market is in its infant stage with intriguing secular tailwinds.
- 05/16/2023
|
Progyny, Inc. (PGNY) Q1 2023 Earnings Call Transcript
- Progyny, Inc. (NASDAQ:PGNY ) Q1 2023 Earnings Conference Call May 8, 2023 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Sarah James - Cantor Fitzgerald Eduardo Ron - Truist Securities Anna Kruszenski - SVB Securities Michael Weisberg - Crestwood Capital Operator Good day, ladies and gentlemen and welcome to the Progyny Inc. First Quarter 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James Hart.
- 05/08/2023
|
Progyny, Inc. to Present at Bank of America Health Care Conference 2023
- NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, Mark Livingston, Chief Financial Officer, and Michael Sturmer, President, will participate in a fireside chat at the Bank of America Health Care Conference 2023 on Tuesday, May 9, 2023, at 2:20 P.M. Pacific Time / 5:20 P.M. Eastern Time.
- 05/02/2023
|
4 Growth Stocks to Buy and Hold Forever
- CrowdStrike and Progyny offer best-in-class solutions to two of today's biggest problems. Texas Pacific believes it has 14 years' worth of oil inventory on its land, with a break-even point of only $40 a barrel.
- 04/27/2023
|
Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
- NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 2:15 P.M. Eastern Time.
- 03/20/2023
|
Want $1 Million in Retirement? Invest $200,000 in These 3 Stocks and Wait a Decade
- Doximity's ability to connect physicians with pharmaceuticals and health systems is a wildly prosperous pairing. Medpace's customers could struggle in 2023, but its long-term opportunity will only grow.
- 03/11/2023
|
Why Shares of Progyny Rose 18.4% This Week
- The company reported record revenue at the beginning of the week.
- 03/03/2023
|
Progyny, Inc. (PGNY) Q4 2022 Earnings Call Transcript
- Progyny, Inc. (NASDAQ:PGNY ) Q4 2022 Earnings Conference Call February 27, 2023 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Michael Cherny - Bank of America Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stephanie Davis - SVB Securities Operator Good day, ladies and gentlemen and welcome to the Progyny Inc. Fourth Quarter 2022 Earnings Call. [Operator Instructions].
- 02/27/2023
|
Progyny (PGNY) Q4 Earnings and Revenues Beat Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 50% and 1.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
Zoom Is Zooming, But This Health-Tech Stock Is Doing Even Better
- Big after-hours gains followed a strong day on Wall Street.
- 02/27/2023
|
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
- Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/30/2023
|
Progyny: Expect Fast Growth Despite A Weak Macro Backdrop
- There is a lack of effective solution in standard fertility benefit packages and PGNY is addressing this gap. PGNY's approach drives down the overall cost.
- 01/29/2023
|
In Search of an Earnings Beat? Play These Top 5 Stocks
- These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).
- 01/19/2023
|
7 Stocks With a Forward P/E of 25 to Run Away From
- With a rough 2022 spilling into 2023, we're running into a broad list of stocks to avoid. Especially those in the tech space, where high-profile layoffs have picked up amid a severe slowdown in growth.
- 01/09/2023
|
4 Unstoppable Multibaggers to Buy in 2023 and Hold for the Next Decade
- Three-year revenue growth rates between 39% and 54% are projected, making these stocks prime multibagger candidates.
- 12/27/2022
|
Progyny: A Winner For Years To Come
- Compared to many newly listed public companies in recent years, Progyny is thriving as client count and revenues have grown tremendously. Progyny is the market leader in the fertility benefits arena, with a proven and successful management team.
- 12/22/2022
|
ELV vs. PGNY: Which Stock Is the Better Value Option?
- ELV vs. PGNY: Which Stock Is the Better Value Option?
- 12/16/2022
|
Looking for Earnings Beat? Buy These 5 Stocks With Potential
- These top-ranked stocks -- Chewy (CHWY), Progyny (PGNY), KnowBe4 (KNBE), Chegg (CHGG) and Fortinet (FTNT) -- are likely to beat on their bottom line in the next releases.
- 12/16/2022
|
Progyny CEO says economic turbulence isn't hurting business
- Cramer spoke with Progyny CEO Peter Anevski on Thursday.
- 12/08/2022
|
ELV vs. PGNY: Which Stock Should Value Investors Buy Now?
- ELV vs. PGNY: Which Stock Is the Better Value Option?
- 11/28/2022
|
Progyny stock grows after fertility drug shipments resume, upping 4Q guidance
- Progyny Inc (NASDAQ:PGNY) announced that shipments of its fertility medication Menopur have resumed following an industry wide shortage, prompting the company to boost its fourth quarter and full year guidance. During the company's earnings call on November 3, executives said that the assumption was that Menopur would not be available for the remainder of 2022.
- 11/28/2022
|
Fertility manager Progyny stock gains as resumption of Menopur deliveries leads to raised guidance
- Shares of Progyny Inc. PGNY, +0.17% gained 0.4% in premarket trading Monday, after the fertility benefits management company raised is fourth-quarter financial outlook, given the surprising resumption of deliveries fertility drug Menopur. The company raised its guidance ranges for fourth-quarter earnings per share to 2 cents to 3 cents from a per-share loss of 1 cents to EPS of 2 cents, and for revenue to $208.9 million to $213.9 million from $202.4 million to $212.4 million.
- 11/28/2022
|
ELV or PGNY: Which Is the Better Value Stock Right Now?
- ELV vs. PGNY: Which Stock Is the Better Value Option?
- 11/11/2022
|
Progyny, Inc. to Present at Credit Suisse 31st Annual Healthcare Conference
- NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022 at 4:25 P.M. Pacific Time, or 7:25 P.M. Eastern Time.
- 11/04/2022
|
Progyny, Inc. (PGNY) CEO Peter Anevski on Q3 2022 Results - Earnings Call Transcript
- Progyny, Inc. (NASDAQ:PGNY ) Q3 2022 Earnings Conference Call November 3, 2022 4:45 PM ET Company Participants James Hart - VP, IR Peter Anevski - CEO Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Glen Santangelo - Jefferies Sarah James - Barclays Stephanie Davis - SVB Securities Deb Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny, Inc. Third Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
- 11/04/2022
|
Progyny (PGNY) Q3 Earnings and Revenues Top Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
ELV or PGNY: Which Is the Better Value Stock Right Now?
- ELV vs. PGNY: Which Stock Is the Better Value Option?
- 10/21/2022
|
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
- Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 09/29/2022
|
AMN or PGNY: Which Is the Better Value Stock Right Now?
- AMN vs. PGNY: Which Stock Is the Better Value Option?
- 09/28/2022
|
MODV vs. PGNY: Which Stock Is the Better Value Option?
- MODV vs. PGNY: Which Stock Is the Better Value Option?
- 09/09/2022
|
Progyny, Inc. to Present at the BofA Securities 2022 Global Healthcare Conference
- NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2022 Global Healthcare Conference on Thursday, September 15, 2022 at 5:50 A.M. Eastern Time, or 10:50 A.M. British Summer Time.
- 09/09/2022
|
This Growth Stock Could Provide Big Long-Term Gains
- A fertility services company aims to help people succeed in starting families.
- 09/01/2022
|
Does Progyny (PGNY) Have the Potential to Rally 64% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 63.5% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/31/2022
|
AMN vs. PGNY: Which Stock Should Value Investors Buy Now?
- AMN vs. PGNY: Which Stock Is the Better Value Option?
- 08/08/2022
|
Progyny, Inc. (PGNY) CEO Peter Anevski on Q2 2022 Results - Earnings Call Transcript
- Progyny, Inc. (NASDAQ:PGNY ) Q2 2022 Earnings Conference Call August 4, 2022 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Sarah James - Barclays Stephanie Davis - SVB Securities Dev Weerasuriya – Berenberg Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to today's Progyny Inc. Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode.
- 08/07/2022
|
Progyny Stock Should Deliver Superior Returns For Investors
- More companies in the U.S. are offering fertility benefits to employees to attract/retain talent and advance the diversity, equity, and inclusion agenda. PGNY has singled itself out as a pure-play fertility benefits management company, building an enviable client roster with 273 clients representing 30+ industries.
- 08/05/2022
|
Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 350% and 2.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Why This Company Still Has a Long Runway for Growth
- A competitive labor landscape makes this company's offerings even more attractive.
- 07/13/2022
|
Progyny: Solving Infertility Problem
- Progyny is a leading benefit management company that specializes in fertility and family building. Their revenue has been growing at an amazing pace (80% per year, 5 year average).
- 07/05/2022
|
AMN or PGNY: Which Is the Better Value Stock Right Now?
- AMN vs. PGNY: Which Stock Is the Better Value Option?
- 06/10/2022
|
Progyny, Inc. to Present at the Jefferies 2022 Healthcare Conference
- NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:30 A.M. Eastern Time.
- 06/01/2022
|
Progyny Stock: A Hidden Gem Tackling Infertility
- Progyny is a hidden gem tackling a prevalent and growing issue. With massive growth ahead and a solid competitive position, Progyny is a great addition to your portfolio.
- 05/31/2022
|
AMN vs. PGNY: Which Stock Is the Better Value Option?
- AMN vs. PGNY: Which Stock Is the Better Value Option?
- 05/25/2022
|
Progyny, Inc. (PGNY) CEO Peter Anevski on Q1 2022 Results - Earnings Call Transcript
- Progyny, Inc. (NASDAQ:PGNY ) Q1 2022 Earnings Call Transcript May 5, 2022 5:00 PM ET Company Representatives Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer James Hart - Vice President of Investor Relations Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Bank of America Sarah James - Barclays Glen Santangelo - Jefferies Stephanie Davis - SVB Securities Dev Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants have been on a listen-only mode and the floor will be opened for questions and comments after the presentation.
- 05/05/2022
|
Progyny: A Profitable High-Growth Company
- Incorporated in 2008, Progyny Inc. ( PGNY , Financial) is a leading benefits management company operating in the fertility space in the United States. The company operates as a third-party insurance company that manages fertility benefit plans, and the most famous product sold by the company is Smart Cycle.
- 05/04/2022
|
Progyny, Inc. to Present at the BofA Securities 2022 Healthcare Conference
- NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced executives from Progyny will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 11:40 A.M. Eastern Time, or 8:40 A.M. Pacific Time.
- 04/28/2022
|
AVTR vs. PGNY: Which Stock Is the Better Value Option?
- AVTR vs. PGNY: Which Stock Is the Better Value Option?
- 04/11/2022
|
2 No-Brainer Stocks to Buy Right Now for Less than $55
- These two healthcare companies have bright futures -- and right now, two-digit price tags.
- 04/05/2022
|
Investors see growth opportunity in Femtech
- Funding for so-called Femtech has more than tripled since 2015. Early stage investors see growth opportunities in companies like breast cancer imaging start-up Clairity, which are looking to close the gap on women's health issues.
- 03/21/2022
|
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?
- OCDX vs. PGNY: Which Stock Is the Better Value Option?
- 03/15/2022
|
Progyny, Inc. to Present at the Barclays Global Healthcare Conference
- NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:50 P.M. Eastern Time.
- 03/10/2022
|
Progyny, Inc. (PGNY) CEO Pete Anevski on Q4 2021 Results - Earnings Call Transcript
- Progyny, Inc. (PGNY) CEO Pete Anevski on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Progyny (PGNY) Surpasses Q4 Earnings Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Progyny, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that Pete Anevski, Progyny's Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 A.M. Eastern Time. Following the presentation, Michael Sturmer, Progyny's President, and Mark Livingston, Progyny's Chief Financial Officer, will join Mr. Anevski for a breakout session.
- 01/05/2022
|
Is Progyny a good buy opportunity at the current share price?
- Progyny, Inc (NASDAQ: PGNY) shares have weakened more than 20% since November 05, even though the company reported strong third-quarter results. Management expects a further business acceleration Progyny is a company that specializes in fertility and family building benefits solutions for employers in the United States by the combination of clinical and emotional support.
- 12/27/2021
|
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
- Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 11/08/2021
|
Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2021 Results - Earnings Call Transcript
- Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Progyny (PGNY) Q3 Earnings Beat Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 142.86% and -2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Progyny: Continued Profitable Growth, Formidable Brand Point To Exciting Upside
- Progyny: Continued Profitable Growth, Formidable Brand Point To Exciting Upside
- 10/20/2021
|
Despite A 25% Rise In A Month Progyny Stock May Continue To See Higher Levels
- The stock price of Progyny (NASDAQ: PGNY), a benefits management company that specializes in fertility and family building benefits solutions, has seen a rise of around 25% over the last month (twenty-one trading days), while it has more than doubled over the last twelve months.
- 09/17/2021
|
Progyny, Inc. to Present at the BofA Global Healthcare Conference
- NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Global Healthcare Conference on Wednesday, September 15, 2021 at 10:55 A.M. Eastern Time, or 3:55 P.M. British Summer Time.
- 09/10/2021
|
Why This Ultra-High-Growth Healthcare Stock Is a Buy
- When a founder-led company is profitably chasing a huge market and having early success, the stock is worth a closer look.
- 09/04/2021
|
5 Medical Services Stocks Countering Industry Headwinds
- The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most.
- 09/01/2021
|
Progyny's (PGNY) CEO David Schlanger on Q2 2021 Results - Earnings Call Transcript
- Progyny's (PGNY) CEO David Schlanger on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Progyny, Inc. to Present at the BofA Securities SMID Cap 2H21 Ideas Conference
- NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, will participate in a fireside chat at the BofA Securities SMID Cap 2H21 Ideas Conference on Tuesday, August 10, 2021 at 1:00 P.M. Eastern Time.
- 08/06/2021
|
Progyny's Stock Is Getting Hammered On Mixed Q2 Earnings; Outlook Lagging Street Consensus
- Progyny Inc (NASDAQ: PGNY) reported Q2 EPS of $0.19, a turnaround from EPS loss of $(0.01) a year ago, edging out analysts' average expectation of $0.08. Sales almost doubled to $128.6 million but missed the consensus of $129.31 million, primarily due to increased clients and covered lives.
- 08/06/2021
|
Progyny: Q2 Earnings Insights
- Shares of Progyny (NASDAQ:PGNY) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 1050.00% over the past year to $0.19, which beat the estimate of $0.08.
- 08/05/2021
|
Progyny Grew 127% In The Last Year And Still Has Room To Run
- Progyny Grew 127% In The Last Year And Still Has Room To Run
- 07/27/2021
|
Progyny, Inc. Announces Details for Its Second Quarter 2021 Results Report
- NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended June 30, 2021 after the close of the market on Thursday, August 5, 2021.
- 07/22/2021
|
Progyny (PGNY) Moves to Strong Buy: Rationale Behind the Upgrade
- Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 07/22/2021
|
Progyny (PGNY) Sees Hammer Chart Pattern: Time to Buy?
- Progyny (PGNY) has been struggling lately, but the selling pressure may be coming to an end soon.
- 07/13/2021
|
7 Must-See Stock Charts That Spell More Upside
- Despite the strong rally in U.S. stocks, there has been volatility too. Here are the seven best stock charts that could spell more upside.
- 07/09/2021
|
I'm selling Progyny this week [June 24th], and this is why!
- Progyny, Inc (NASDAQ: PGNY) shares have advanced more than 40% since the beginning of January 2021, and the current share price stands around $59. Progyny expects adjusted EBITDA between $70 million to $75 million for the 2021 fiscal year, but even this doesn't justify its current stock price.
- 06/23/2021
|
Here's Why Progyny (PGNY) is a Great Momentum Stock to Buy
- Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/23/2021
|
Progyny's (PGNY) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Progyny, Inc. (PGNY)
- 06/10/2021
|
Progyny, Inc. to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
- NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 3:50 P.M. Eastern Time.
- 06/04/2021
|
Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy?
- Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 06/02/2021
|
Welltok Welcomes Maven and Progyny to its Connect Ecosystem Family
- DENVER, May 19, 2021 /PRNewswire/ -- Family planning and fertility benefits are becoming more mainstream with employers seeking to demonstrate inclusivity and attract or retain talent. As women become mothers later in their career and same-sex couples or single people seek to have children, there has been greater interest and expectations for these benefits.
- 05/19/2021
|
Progyny, Inc. (PGNY) CEO David Schlanger on Q1 2021 Results - Earnings Call Transcript
- Progyny, Inc. (PGNY) CEO David Schlanger on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Progyny, Inc. to Present at the BofA Securities 2021 Health Care Conference
- NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 10:15 A.M. Eastern Time.
- 05/07/2021
|
Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 87.50% and 0.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Progyny, Inc. Announces First Quarter 2021 Results
- Reports Record First Quarter Revenue of $122.1 Million, Reflecting 51% GrowthIssues Revenue Guidance of $126.0 to $131.0 Million for the Second Quarter of 2021, Reflecting Growth of 95% to 103%Continues to Demonstrate Leverage in Operating Model Through Increased Profitability
- 05/06/2021
|
Progyny, Inc. Announces Details for Its First Quarter 2021 Results Report
- NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended March 31, 2021 after the close of the market on Thursday, May 6, 2021.
- 04/22/2021
|
Benefits Manager Progyny Grows Even As Covid Upends Fertility Treatments
- When the coronavirus pandemic blanketed the U.S. last year, couples put off pregnancy plans. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 04/16/2021
|
PTC Set to Join S&P 500; Lattice Semiconductor & Progyny to Join S&P MidCap 400; Domtar to Join S&P SmallCap 600
- NEW YORK, April 15, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the open of trading on Tuesday, April 20: S&P MidCap 400 constituent PTC Inc. (NASD:PTC) will replace Varian Medical Systems Inc. (NYSE:VAR) in the S&P 500, and Lattice Semiconductor Co. (NASD:LSCC) will replace PTC in the S&P MidCap 400. Siemens Healthineers AG (XETR: SHL) acquired Varian Medical Systems Inc. in a deal that closed today, April 15.
- 04/15/2021
|
3 Stock Picks With High Returns on Equity
- When a company's return on equity ratio tops most of its competitors, it indicates the company has been very efficient in generating earnings.
- 04/14/2021
|
Top Stocks To Buy This Month Amid Optimistic Markets
- Netflix and Facebook are among the top stocks for April. Q.ai's Artificial Intelligence has also dug up top tech stocks, top consumer stocks, top quality value stocks, and top growth stocks.
- 04/07/2021
|
Top Stocks To Short Today As Major Indices Trade In The Red
- Amid real potential for another sell-off, the deep learning algorithms at Q.ai have crunched the data to give you top shorts for today.
- 03/25/2021
|
Top Stocks To Short Today As Investors Buckle Up For Bond Yields
- Growth stocks opened the day with significant losses as the 10-year yield climbed to its highest level since last January. But Q.ai's deep learning algorithms have assessed the data to bring you today's best short plays.
- 03/18/2021
|
Top Stocks To Short Today As The Fed Keeps Investors On Their Toes
- Although the Dow Jones gained 40 points, the S&P 500 fell 0.4%, and the Nasdaq dropped 1.1%. Q.ai's deep learning algorithms are here to help you make the most of this market with today's best short plays.
- 03/17/2021
|
Top Stocks To Short Today As Market Struggles To Reverse Losing Streak
- Stocks have dropped again due to bond yields. In the meantime, Q.ai's Artificial Intelligence has assessed the data to bring you today's best short plays.
- 03/04/2021
|
Progyny, Inc. (PGNY) CEO David Schlanger on Q4 2020 Results - Earnings Call Transcript
- Progyny, Inc. (PGNY) CEO David Schlanger on Q4 2020 Results - Earnings Call Transcript
- 02/24/2021
|
Progyny, Inc. Announces Fourth Quarter and Full Year 2020 Results
- Reports Record Fourth Quarter Revenue of $100.3 MillionIssues Revenue Guidance of $520.0 to $540.0 Million for 2021, Reflecting Growth of 51% to 57%
- 02/24/2021
|
2 High-Growth Stocks in the Market Today
- Why these two stocks are strong buys.
- 02/22/2021
|
Progyny, Inc. to Participate at the 10th Annual SVB Leerink Global Healthcare Conference
- NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Progyny's Chief Financial Officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 A.M. Eastern Time.
- 02/22/2021
|
3 Healthcare Stocks I'd Buy Right Now
- Two innovative small companies with scorching growth and one bargain biotech.
- 02/15/2021
|
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year Results Report
- NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period and full year ended December 31, 2020 after the close of the market on Wednesday, February 24, 2021.
- 02/10/2021
|
Here's Why Investors Should Put Progyny on Their Radar
- This fertility stock could have serious long-term potential.
- 01/20/2021
|
5 Top Stock Trades for Tuesday: NIO, FIVN, TLRY, PGNY, BB
- Nio, BlackBerry, Tilray, Five9 and Progyny were our top stock trades for Tuesday. Let's check out the charts after a long holiday weekend.
- 01/19/2021
|
Progyny Strengthens Board of Directors with Appointments of Healthcare and Technology Leaders
- NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced the appointment of two new members to its board of directors, effective November 16, 2020. Joining the board are Malissia R. Clinton, Senior Vice President, General Counsel, and Secretary of The Aerospace Corporation and Roger Holstein, Managing Director of Vestar Capital Partners.
- 11/18/2020
|
Progyny, Inc. Announces Participation at the Piper Sandler Healthcare Conference
- NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
- 11/16/2020
|
Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2020 Results - Earnings Call Transcript
- Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Progyny Grows Business But Stock May Be Priced For Perfection
- Progyny went public in October 2019, raising $130 million. The firm provides fertility and family planning benefit services in the United States.
- 11/06/2020
|
Progyny (PGNY) Q3 Earnings Meet Estimates
- Progyny (PGNY) delivered earnings and revenue surprises of 0.00% and 6.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/05/2020
|
Progyny: Q3 Earnings Insights
- Shares of Progyny (NASDAQ:PGNY) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 66.67% over the past year to $0.05, which were in line with the estimate of $0.05.
- 11/05/2020
|
